OP57 – Identification and Validation of Long Noncoding RNA Biomarkers for Human Papillary Thyroid Carcinomas

      Guo, Kai1,2; Qian, Kai1,2 ; Sun, Tuanqi1,2; Li, Duanshu1.2; Zheng, Xiaoke1,2; Wu, Yi1.2; Ji, Qinghai1.2; Wang, Zhuoying1,2  1 Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China 2 Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China   Background: Long non-coding RNAs (lncRNAs) have been reported to play an important role in regulating the pathological process of human cancers, yet these were poorly understood in Papillary Thyroid Carcinoma (PTC) patients. Objectives: The aim of this study was to exploit the genome-wide expression and functional significant lncRNAs in PTCs. Methods: We performed RNA sequencing of four paired PTC tumors and matched noncancerous tissues, and carried out an integrated analysis with a publicly available PTC microarray dataset (GSE66783). In addition, an independent cohort of 60 clinical samples was analyzed to validate these lncRNAs by quantitative polymerase chain reaction (q-PCR). Then we use The Atlas of Noncoding RNAs in Cancer (TANRIC) to predict the function of these lncRNAs. Results: Microarray analysisrevealed that 4337 lncRNAs were abnormally expressed in the four PTC samples compared with adjacent noncancerous samples (fold change>1.5, P<0.05). This was refined to a list of 66 significantly differentially expressed lncRNAs (false discovery rate < 0.05), using Significance Analysis of Microarrays (SAM) analysis. Q-PCR analysis of the four lncRNAs tested was consistent with the microarray data. Through prediction of TANRIC, we found MIR31HG, UNC5B-AS1, CYP1B1 and LINC00881 was associated with BRAF mutation, MIR31HG, CYP1B1, LINC00881, PROSER2 and LINC00893 was associated with NRAS, CYP1B1, LINC00881 and DPH6-AS1 was associated with HRAS. Conclusions: We have identified and validated a series of novel PTC?associated lncRNAs. Further study of these lncRNAs will be exploited for the identification of novel and useful molecular biomarkers that may lead to improvement in diagnosis and treatment for PTC.


Leave a Reply